Biogen (BIIB) Tops Q3 EPS by 31c; raises guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $220.83 -1.64%
EPS Growth %: -57.8%
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -57.8%
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.08, $0.31 better than the analyst estimate of $3.77. Revenue for the quarter came in at $2.47 billion versus the consensus estimate of $2.43 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $16.10-$16.60, versus the consensus of $16.19.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
- FDA grants accelerated approval to AstraZeneca's camizestrant combo
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
